Scientific Reports (Aug 2017)

Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients

  • Fei-Yan Xiao,
  • Jian-Quan Luo,
  • Min Liu,
  • Bi-Lian Chen,
  • Shan Cao,
  • Zhao-Qian Liu,
  • Hong-Hao Zhou,
  • Gan Zhou,
  • Wei Zhang

DOI
https://doi.org/10.1038/s41598-017-07736-1
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Carboxylesterase 1 (CES1) hydrolyzes the prodrug clopidogrel to an inactive carboxylic acid metabolite. The effects of CES1 S75N (rs2307240,C>T) on clopidogrel response among 851 acute coronary syndrome patients who came from the north, central and south of China were studied. The occurrence ratios of each endpoint in the CC group were significantly higher than in the CT + TT group for cerebrovascular events (14% vs 4.8%, p < 0.001, OR = 0.31), acute myocardial infarction (15.1% vs 6.1%, p < 0.001, OR = 0.37) and unstable angina (62.8% vs 37.7%, p < 0.001, OR = 0.36). The results showed that there was a significant association between CES1 S75N (rs2307240) and the outcome of clopidogrel therapy. Moreover, the frequency of the T allele of rs2307240 in acute coronary syndrome patients (MAF = 0.22) was more than four times higher than that in the general public (MAF = 0.05).